Technology from the laboratories of IOCB Prague has been given an extraordinary opportunity to succeed in the rapidly developing segment of gene therapy. The results of successful research are set to be advanced by a newly established private company called Adalid Sciences, which is being supported with a major investment from BTL Group, a leading manufacturer of medical technologies. The story begins with the discovery of new lipid nanoparticles with a comic book name coined by Dr. Petr Cígler and Dr. Klára Grantz Šašková of IOCB Prague. Acting as a sort of imaginary courier, their XMAN is capable of safely transporting nucleic acids, either the basic building blocks of DNA or the long strands of RNA, into cells. At the same time, the potential of such a molecular transport device is constantly growing because the field of gene therapy has… 

Medivir AB (NASDAQ: MVIR) (STOCKHOLM: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that it has selected a global CRO partner for the planned phase 2b study evaluating fostroxacitabine bralpamide (fostrox) + Lenvima® vs Lenvima alone in second line HCC. In the next phase of development, Medivir is planning for a global, randomized phase 2b study aligned with its recent supportive Type C interaction with the FDA. The objective is to evaluate the combination of fostrox + Lenvima in second line advanced HCC with the aim of becoming the first, approved treatment alternative after current first line treatment. The study is planned to enroll patients broadly in the US, EU and Asia, building on countries and sites participating in currently ongoing phase 1b/2a, which will ensure that recruitment… 

Daewoong Pharmaceutical (CEOs Chang-jae Lee and Seongsoo Park) announced that it will present the pooled analysis results of the Phase 3 clinical trials for Enavogliflozin at the 84th American Diabetes Association conference in Orlando, USA, from June 21 to 24. These results showcase Enavogliflozin’s efficacy and safety in patients with mild renal impairment who struggle with blood glucose control. Professor Lyu Young-sang from the Endocrinology and Metabolism Department at Chosun University Hospital will present the study, which includes the pooled analysis results of the Phase 3 clinical trial of Enavogliflozin combined with metformin. The findings highlight Enavogliflozin’s superior blood glucose-lowering effects compared to dapagliflozin in type 2 diabetes patients with mild renal impairment. The presentation will cover Enavogliflozin’s enhanced blood glucose control, increased urinary glucose excretion, and improved insulin resistance. The study shows Enavogliflozin’s superior blood glucose-lowering effects compared to… 

Recently, Professor Jianping Weng of the University of Science and Technology of China (USTC) and President of Anhui Medical University and his team of researchers from USTC, Southern Medical University and Peking University published the results of their latest research on the effects of early insulin therapy on cardiovascular health in adults with Type 2 Diabetes Mellitus (T2DM) in the journal Signal Transduction and Targeted Therapy. This study is the first in the world to demonstrate that early insulin therapy is associated with a significant reduction in the incidence of cardiovascular events in newly diagnosed patients with T2DM. This research signifies a breakthrough in the field of diabetes treatment, compelling us to rethink the diabetes treatment model.